Annual Accounts Receivable
$6.60 M
-$3.32 M-33.47%
December 31, 2022
Summary
- As of February 10, 2025, SELB annual accounts receivable is $6.60 million, with the most recent change of -$3.32 million (-33.47%) on December 31, 2022.
- During the last 3 years, SELB annual accounts receivable has risen by +$1.60 million (+31.92%).
Performance
SELB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Accounts Receivable
$4.90 M
-$487.00 K-9.04%
September 30, 2023
Summary
- As of February 10, 2025, SELB quarterly accounts receivable is $4.90 million, with the most recent change of -$487.00 thousand (-9.04%) on September 30, 2023.
- Over the past year, SELB quarterly accounts receivable has dropped by -$2.03 million (-29.27%).
Performance
SELB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
SELB Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -33.5% | -29.3% |
| 3 y3 years | +31.9% | -61.2% |
| 5 y5 years | - | - |
SELB Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -33.5% | at low | -79.6% | at low |
| 5 y | 5-year | -33.5% | -24.2% | -79.6% | -100.0% |
| alltime | all time | -33.5% | -100.0% | -79.6% | -100.0% |
Selecta Biosciences Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $4.90 M(-9.0%) |
| Jun 2023 | - | $5.38 M(-21.3%) |
| Mar 2023 | - | $6.84 M(+3.7%) |
| Dec 2022 | $6.60 M(-33.5%) | $6.60 M(-4.8%) |
| Sep 2022 | - | $6.92 M(-71.1%) |
| Jun 2022 | - | $23.99 M(+235.4%) |
| Mar 2022 | - | $7.15 M(-27.8%) |
| Dec 2021 | $9.91 M(+37.2%) | $9.91 M(+35.4%) |
| Sep 2021 | - | $7.32 M(-13.5%) |
| Jun 2021 | - | $8.46 M(+1.5%) |
| Mar 2021 | - | $8.34 M(+15.5%) |
| Dec 2020 | $7.22 M | $7.22 M(-42.8%) |
| Sep 2020 | - | $12.63 M(>+9900.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $0.00(-100.0%) |
| Dec 2019 | $5.00 M(>+9900.0%) | $5.00 M(>+9900.0%) |
| Dec 2018 | $0.00(-100.0%) | $0.00(-100.0%) |
| Mar 2018 | - | $52.00 K(>+9900.0%) |
| Sep 2017 | - | $0.00(-100.0%) |
| Jun 2017 | - | $1000.00(-98.4%) |
| Mar 2017 | - | $63.00 K(-70.7%) |
| Dec 2016 | $215.00 K(-73.9%) | $215.00 K(-55.5%) |
| Sep 2016 | - | $483.00 K(-75.4%) |
| Jun 2016 | - | $1.96 M(+20.5%) |
| Mar 2016 | - | $1.63 M(+97.5%) |
| Dec 2015 | $824.00 K(+22.3%) | $824.00 K |
| Dec 2014 | $674.00 K | - |
FAQ
- What is Selecta Biosciences annual accounts receivable?
- What is the all time high annual accounts receivable for Selecta Biosciences?
- What is Selecta Biosciences annual accounts receivable year-on-year change?
- What is Selecta Biosciences quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Selecta Biosciences?
- What is Selecta Biosciences quarterly accounts receivable year-on-year change?
What is Selecta Biosciences annual accounts receivable?
The current annual accounts receivable of SELB is $6.60 M
What is the all time high annual accounts receivable for Selecta Biosciences?
Selecta Biosciences all-time high annual accounts receivable is $9.91 M
What is Selecta Biosciences annual accounts receivable year-on-year change?
Over the past year, SELB annual accounts receivable has changed by -$3.32 M (-33.47%)
What is Selecta Biosciences quarterly accounts receivable?
The current quarterly accounts receivable of SELB is $4.90 M
What is the all time high quarterly accounts receivable for Selecta Biosciences?
Selecta Biosciences all-time high quarterly accounts receivable is $23.99 M
What is Selecta Biosciences quarterly accounts receivable year-on-year change?
Over the past year, SELB quarterly accounts receivable has changed by -$2.03 M (-29.27%)